RESUMEN
Intravascular lymphoma (IVL) is a rare extra nodal subtype (usually of B-cell origin) presenting with infiltration of large neoplastic lymphocytes into lumina of blood vessels, leading to vascular occlusion. The early diagnosis is very crucial, however it is usually diagnosed postmortem investigation in most of the cases. A 56-year-old female presented with elevated creatinine level, and anasarca-type edema that superimposed with hard, indurated, erythematous plaques extending to inguinal region, abdomen, anterior aspect of chest, and face. B-cell IVL was confirmed with skin biopsy. The patient had some degree of clinical improvement following chemotherapy. B-cell IVL presenting with anasarca edema was not previously reported in the literature. Even if its rarity, IVL should be considered in the differential diagnosis of renal failure with anasarca edema.
Asunto(s)
Lesión Renal Aguda/etiología , Edema/etiología , Linfoma de Células B Grandes Difuso/patología , Neoplasias Cutáneas/patología , Neoplasias Vasculares/patología , Lesión Renal Aguda/patología , Edema/patología , Femenino , Humanos , Linfoma de Células B Grandes Difuso/complicaciones , Persona de Mediana Edad , Neoplasias Cutáneas/complicaciones , Neoplasias Vasculares/complicacionesRESUMEN
BACKGROUND AND OBJECTIVE: Prolonged corticosteroid (CS) use induces osteoporosis; the pathogenesis of this condition is multifactorial and includes CS-induced hypercalciuria. We investigated the course of hypercalciuria and related markers of bone metabolism parameters during and after the CS treatment. MATERIALS AND METHODS: We recruited 42 patients who were taking at least 10 mg/day of methylprednisolone or an equivalent dose of CSs for at least 30 days. The 24-h urinary calcium and sodium, a spot urinary calcium/creatinine ratio, and urinary deoxypyridinoline were measured prior to the treatment, at day 7, at days 30-60, and after the cessation of the treatment. Additionally, the serum levels of phosphorus, calcium, alkaline phosphatase (ALP), albumin, creatinine, osteocalcin, and parathyroid hormone (PTH) were analyzed. RESULTS: The 24-h urinary calcium excretion was significantly increased at day 7 (182.2 ± 158.6 mg/day; p < 0.001) and at days 30-60 (196.9 ± 167.8 mg/day; p < 0.001) compared with baseline (98.7 ± 88.1 mg/day) and returned to basal level after the cessation of the CSs (118.9 ± 90.2 mg/day; p = 0.725). The urinary deoxypyridinoline level was significantly higher at days 30-60 compared with basal level. The serum osteocalcin level was decreased at days 30-60 when compared with day 7. No significant changes were detected in the PTH, phosphorus, creatinine, and ALP levels. CONCLUSIONS: CS treatment induces hypercalciuria just after starting the treatment until the end of it. CS-induced hypercalciuria promptly improved after cessation of the treatment. By days 30-60, the excretion of urinary deoxypyridinoline was accompanied by hypercalciuria. The serum osteocalcin level was decreased at days 30-60 when compared with day 7.
Asunto(s)
Biomarcadores/metabolismo , Huesos/metabolismo , Glucocorticoides/efectos adversos , Hipercalciuria/metabolismo , Metilprednisolona/efectos adversos , Osteoporosis/inducido químicamente , Adolescente , Adulto , Anciano , Aminoácidos/orina , Huesos/efectos de los fármacos , Calcio/orina , Creatinina/sangre , Creatinina/orina , Relación Dosis-Respuesta a Droga , Femenino , Glucocorticoides/administración & dosificación , Humanos , Hipercalciuria/inducido químicamente , Masculino , Metilprednisolona/administración & dosificación , Persona de Mediana Edad , Osteocalcina/sangre , Osteoporosis/metabolismo , Hormona Paratiroidea/sangre , Factores de Riesgo , Sodio/orina , Adulto JovenRESUMEN
Rhabdomyolysis is defined as a pathological condition of skeletal muscle cell damage leading to the release of toxic intracellular components into the circulation. Several factors may lead to rhabdomyolysis. Fenofibrate is a fibric acid derivative agent that is used in the treatment of hyperlipidaemia. Although several case reports of rhabdomyolysis have been reported due to the combination of statin and fenofibrate, fenofibrate alone rarely causes rhabdomyolysis. When administering fenofibrate in chronic renal failure, dose should be adjusted. Here, we report a case with fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure.
Asunto(s)
Diabetes Mellitus Tipo 2/complicaciones , Fenofibrato/efectos adversos , Fallo Renal Crónico/complicaciones , Rabdomiólisis/inducido químicamente , Diagnóstico Diferencial , Femenino , Fenofibrato/uso terapéutico , Humanos , Hipolipemiantes/efectos adversos , Fallo Renal Crónico/diagnóstico , Persona de Mediana Edad , Rabdomiólisis/diagnósticoRESUMEN
OBJECTIVE: To characterise the relationship between visfatin levels and various clinical and biochemical parameters in peritoneal dialysis patients. METHODS: The case-control study was conducted at the Medical Faculty Hospital, Yuzuncu Yil University, Van, Turkey, between May 2007 and December 2008, and involving 41 patients on peritoneal dialysis, 20 haemodialysis patients and 20 healthy controls. Fasting visfatin level was measured with enzyme-linked immunosorpent assay (ELISA) method, and patients on peritoneal dialysis were separated into two groups according to the visfatin levels - high and low. The groups were compared in terms of some clinical (height, weight, body mass index, waist circumference, hip circumference, waist/hip ratio, heart rate, systolic and diastolic blood pressure and the kt/V and CrCI (creatanine clearance) parameters which are indicative of the dialysis adequacy) and biochemical parameters (glucose, triglycerides, cholesterol, low density lipoprotein, high density lipoprotein, aspartate aminotransferase, alanine transminase, blood urea nitrogen, creatinine, total protein, albumin, globulin, sodium, potassium, magnesium, calcium, phosphorus, ferritin, venous blood gas, parathyroid hormone and insulin). SPSS 15 was used for statistcal analysis. RESULTS: No statistically significant difference in the visfatin levels was found between the patients and controls (7.71 +/- 4.04, 7.36 +/- 3.71, 7.70 +/- 1.61, respectively, p = 0.63). The triglyceride level of the high-visfatin group was significantly higher than that of the low-visfatin group (243.8 +/- 133.2, 150.8 +/- 65.8, respectively, p<0.05). However, there was no correlation between visfatin and triglyceride levels. No difference in the other clinical and biochemical parametres was observed between the two groups of peritoneal dialysis patients. CONCLUSIONS: No significant difference in the serum visfatin levels of peritoneal dialysis patients compared to haemodialysis patients or healthy individuals was noticed. Further studies are needed to confirm the effect of visfatin on triglyceride levels, and, if confirmed, the mechanism of this relation.
Asunto(s)
Nicotinamida Fosforribosiltransferasa/sangre , Diálisis Peritoneal , Adulto , Análisis de Varianza , Antropometría , Biomarcadores/sangre , Estudios de Casos y Controles , Distribución de Chi-Cuadrado , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estadísticas no Paramétricas , TurquíaRESUMEN
Increased oxidative stress is a well-known phenomenon in dialysis patients. However, the contribution of hypertension to the oxidative stress in peritoneal dialysis patients has not yet been assessed. The present study aimed to investigate if hypertension had an additional effect on oxidative stress in peritoneal dialysis patients. A total of 50 patients treated with peritoneal dialysis were divided into two groups: The patients with mean of last three blood pressure results as 135/90 mmHg and above were considered hypertensive, the patients with lower blood pressure were considered normotensive. The control group included 25 healthy individuals. Serum malondialdehyde (MDA), advanced oxidation protein product (AOPP), myeloperoxidase (MPO), catalase (CAT) and glutathione peroxidase (GSH-Px) levels were measured in all groups. MDA level, an indicator of lipid peroxidation, was significantly higher in the hypertensive group compared to the control group, while the increase in the normotensive group was not significant. However, the difference between the hypertensive and normotensive groups was significant. The levels of AOPP, an indicator of protein oxidation level, and MPO, an indicator of neutrophil activation, were not different between the groups, while the activities of antioxidant CAT and GSH-Px decreased in both normotensive and hypertensive groups compared to the control group, and there was no significant difference between the patient groups. This study shows that both normotensive and hypertensive peritoneal dialysis patients have increased-oxidative stress and decreased antioxidant levels and hypertension might have an additional effect on oxidative stress by increasing MDA level in peritoneal dialysis patients.
Asunto(s)
Hipertensión/sangre , Estrés Oxidativo , Diálisis Peritoneal , Antioxidantes/metabolismo , Presión Sanguínea , Monitoreo Ambulatorio de la Presión Arterial , Catalasa/sangre , Femenino , Glutatión/sangre , Glutatión Peroxidasa/sangre , Humanos , Hipertensión/fisiopatología , Fallo Renal Crónico/sangre , Fallo Renal Crónico/terapia , Peroxidación de Lípido , Masculino , Malondialdehído/sangre , Persona de Mediana Edad , Activación Neutrófila , Oxidación-Reducción , Peroxidasa/sangre , Superóxido Dismutasa/sangreRESUMEN
BACKGROUND: Calcineurin inhibitor cyclosporine A (CsA) is a potent immunosuppressive agent. The side effects of CsA include nephrotoxicity, hypertension, hypertrichosis, infection, hyperpotassemia, and, to a lower extent, neuropathy. OBJECTIVES: In this case report, we aimed to present a renal transplant patient with polyneuropathy (PNP) due to the use of CsA and with improvement when switched to rapamycin. METHODS: In electromyography, axonal sensory PNP was detected. CsA was stopped and rapamycin was begun. RESULTS: His complaints rapidly improved after using rapamycin. CONCLUSIONS: Patients using CsA should be closely monitored for peripheral neuropathy and in case of toxicity, alternative immunosuppressive agents should be considered.
Asunto(s)
Ciclosporina/efectos adversos , Inmunosupresores/efectos adversos , Trasplante de Riñón , Polineuropatías/inducido químicamente , Electromiografía , Humanos , Masculino , Persona de Mediana Edad , Polineuropatías/diagnósticoRESUMEN
BACKGROUND: The relationship between increased serum enzyme activity of prolidase and increased rate of collagen turnover in the arterial wall has been asserted in previous studies. Collagen reflects much of the strength to the connective tissue involved in the arterial wall. Atherosclerosis is very common vessel disease and oxidative stress plays a pivotal role in the etiopathogenesis. Our objective was to examine the serum enzyme activity of prolidase and its possible relationships with oxidative stress parameters in obese subjects. METHODS: Our present study was conducted 27 obese subjects and 26 age-matched healthy control subjects. The serum enzyme activity of prolidase in all study population was evaluated spectrophotometrically. Oxidative stress levels in obese subjects were analyzed with total antioxidant capacity (TAC) and total oxidant status (TOS) as well as oxidative stress index (OSI). RESULTS: Obese subjects have higher serum TOS and OSI indicators as well as prolidase activity than those in control subjects (for all; p<0.001). Moreover, obese subjects have lower levels of TAC than in those in healthy subjects (p<0.001). In the Pearson's correlation analysis, enzyme activity of prolidase was positively related with TOS (p<0.001, r=0.529) and OSI (p<0.001, r=0.519) as well as BMI (p<0.001, r=0.692) and inversely related with TAC (p<0.05, r=-0.405) in obese subjects. CONCLUSIONS: Increased serum prolidase activity and decreased antioxidant levels are likely to be a results of increased of oxidative stress levels in obese subjects. The significantly correlation between increased oxidative stress and increased prolidase activity may play a pivotal role in etiopathogenesis of atherosclerotic cardiovascular diseases in obese subjects.
Asunto(s)
Dipeptidasas/sangre , Obesidad/sangre , Obesidad/metabolismo , Estrés Oxidativo , Adulto , Biomarcadores/metabolismo , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Obesidad/enzimologíaRESUMEN
OBJECTIVES: Some studies have indicated the pathophysiological importance of reactive oxygen species (ROS) in patients with nephrotic syndrome. Myeloperoxidase (MPO) is a leukocyte-derived enzyme-generating ROS that has been proposed to exert a wide array of pro-atherogenic effects throughout all stages of the atherosclerotic process. The aim of this study was to investigate the serum malondialdehyde (MDA) levels, MPO and catalase activities in patients with adult nephrotic syndrome. PATIENTS AND METHOD: s Twenty-four patients with nephrotic syndrome and 24 healthy controls were enrolled. Serum MPO activity, catalase activity, and MDA levels were assessed. RESULTS: Serum MPO activity and MDA levels were significantly higher in patients with nephrotic syndrome than controls (both, P<0.001), while catalase activity was significantly lower (P<0.001). Serum catalase activity was found to be significantly correlated with MPO activity (r=-0.417, P=0.003) and MDA levels (r=-0.532, P=0.007). The serum MDA levels were also found to be significantly correlated with MPO activity (r=0.419, P=0.003). CONCLUSIONS: We concluded that serum MPO activity and oxidative stress were increased and that serum catalase activity was decreased in patients with adult nephrotic syndrome. In addition, these results indicate that increased MPO activity is associated with an oxidant-antioxidant imbalance that may contribute to atherosclerosis in patients with adult nephrotic syndrome.
Asunto(s)
Catalasa/sangre , Malondialdehído/sangre , Síndrome Nefrótico/sangre , Estrés Oxidativo , Peroxidasa/sangre , Adulto , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , Síndrome Nefrótico/fisiopatologíaRESUMEN
AIM: We aimed to evaluate the frequency of catheter-related internal jugular vein (IJV) thrombosis, associated factors, and the anatomical variations of IJV in hemodialysis patients. MATERIAL AND METHODS: Hemodialysis patients were evaluated with B-mode ultrasonography (USG). Participants in the prospective group were evaluated using USG prior to catheter insertion, 10 days after catheter insertion, at the time of catheter removal, and 15 days after removal. RESULTS: The rate of thrombosis was increased correlated with the number of catheter insertions. These rates were 14%, 15%, and 47% in those undergoing catheter insertion once, twice, and three times, respectively (P < .05). The anatomical variations of IJV were 21% in the retrospective cases. No significant relationship was found between anatomical variations and thrombosis and between some biochemical parameters and thrombosis. CONCLUSION: Catheter-related IJV thrombosis is frequent in hemodialysis patients. Long catheter remaining time and repeated catheterization increase the thrombosis rate.
Asunto(s)
Catéteres Venosos Centrales/efectos adversos , Venas Yugulares/diagnóstico por imagen , Diálisis Renal/efectos adversos , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/epidemiología , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Ultrasonografía , Trombosis de la Vena/etiologíaRESUMEN
OBJECTIVES: Fenofibrate is a fibric acid derivative that is used alone or combination with statins in the treatment of hyperlipidemia. These drugs have potential risks, including rhabdomyolysis and acute renal failure. Despite reports of rhabdomyolysis with the use of fenofibrate alone or with statin-fibrate combinations, there have been no cases of rhabdomyolysis described when fenofibrate was used alone to treat patients with chronic renal failure owing to nephrotic syndrome. DESIGN AND METHODS: We report on a 26-year-old male who presented with fenofibrate-induced rhabdomyolysis with chronic renal failure due to nephrotic syndrome. RESULTS: After the discontinuation of fenofibrate, the patient was treated with intravenous fluid replacement and urine alkalization. Subsequently, his clinical and biochemical findings improved. CONCLUSIONS: Before starting fenofibrate therapy, the causes of secondary hyperlipidemia, especially nephrotic syndrome, should be investigated. In the presence of chronic renal failure and hypoalbuminemia, the fenofibrate dose should be adjusted. Physicians should be aware of the potential toxicities of fenofibrate, and patients should be informed about its potential side effects.
Asunto(s)
Fenofibrato/efectos adversos , Fenofibrato/farmacología , Hipolipemiantes/efectos adversos , Hipolipemiantes/farmacología , Fallo Renal Crónico/tratamiento farmacológico , Rabdomiólisis/tratamiento farmacológico , Adulto , Fatiga/diagnóstico , Humanos , Hipertensión/complicaciones , Hipoalbuminemia/tratamiento farmacológico , Masculino , Resultado del TratamientoRESUMEN
INTRODUCTION: In patients with chronic kidney disease (CKD) predisposition to bleeding is frequently seen due to disturbances in platelet adhesion and aggregation. Various tests have been utilized to evaluate the disturbance of hemostasis in end-stage renal disease patients. In this trial; we evaluated skin bleeding time in patients admitted to our hospital with uremic symptoms and having hemodialysis (HD) for the first time. We also examined the effects of HD and uremia on this test and investigated its effectiveness in predicting the hemorrhagic complications before implementation of invasive procedures in uremic patients. MATERIAL-METHOD: Twenty nine patients (13 men,16 women; mean age 59.7 ± 18.1) with CKD who presented with symptoms of uremia and treated with HD for the first time were enrolled in this trial. The skin bleeding time were measured before initiation of first hemodialysis and after the second hemodialysis session. RESULTS: The skin bleeding time after the second dialysis was significantly shorter when compared to pre-dialysis values (p < 0.05). Correlation analysis between the skin bleeding time and urea, creatinine, hemoglobin, platelet, and bicarbonate showed no correlation. CONCLUSIONS: Skin bleeding time could reveal the uremic platelet dysfunction and beneficial effect of dialysis in the patients who presented with uremic symptoms and treated with HD for the first time. We suggest that skin bleeding time may be an appropriate test for the evaluation of hemostasis disturbance in uremic patients and prediction of the bleeding risk before invasive procedures.
Asunto(s)
Tiempo de Sangría , Trastornos de las Plaquetas Sanguíneas/diagnóstico , Plaquetas/fisiología , Diálisis Renal , Piel/irrigación sanguínea , Uremia/sangre , Adulto , Anciano , Bicarbonatos/sangre , Trastornos de las Plaquetas Sanguíneas/sangre , Trastornos de las Plaquetas Sanguíneas/etiología , Ensayos Clínicos como Asunto/estadística & datos numéricos , Creatinina/sangre , Femenino , Hematócrito , Hemoglobinas/análisis , Humanos , Fallo Renal Crónico/sangre , Fallo Renal Crónico/complicaciones , Fallo Renal Crónico/terapia , Masculino , Persona de Mediana Edad , Urea/sangre , Uremia/etiología , Uremia/terapiaRESUMEN
Metformin is an oral antidiabetic, which is frequently used in the treatment of type II diabetes mellitus. Serious side effects may be seen during the administration of high doses of metformin. Two cases of lactic acidosis due to ingestion of high dose metformin for suicidal purposes have been presented here; in both cases, clinical improvement was seen with bicarbonate hemodialysis.
Asunto(s)
Acidosis Láctica/terapia , Bicarbonatos/administración & dosificación , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/toxicidad , Metformina/toxicidad , Diálisis Renal/métodos , Acidosis Láctica/inducido químicamente , Acidosis Láctica/metabolismo , Adolescente , Diabetes Mellitus Tipo 2/metabolismo , Soluciones para Diálisis , Humanos , Ácido Láctico/sangre , Masculino , Intento de Suicidio , Resultado del TratamientoRESUMEN
Data on the antioxidant levels enzyme in patients with hyperthyroidism are limited and conflicting. Therefore, the objective of this study was to evaluate the oxidative status using an automated method in patients with hyperthyroidism. Thirty-six subjects with hyperthyroidism and 30 healthy controls were enrolled in this study. Serum oxidative status was determined via measurement of total antioxidant capacity (TAC) and total oxidant status (TOS) and calculation of oxidative stress index (OSI). Serum TAC levels were significantly lower in patients with hyperthyroidism than controls (P=0.002), while serum TOS levels and OSI values were significantly higher (P=0.008, 0.004; respectively). Serum TAC levels were correlated with TSH levels (rho=0.223, P=0.032), FT3 levels (rho=-0.434, P=0.002) and FT4 levels (rho=-0.363, P=0.003) in patients. Further, TOS levels and OSI values were correlated with TSH levels (rho=-0.245, P=0.037; rho=-0.312, P=0.011, respectively), FT3 levels (rho=0.293, P=0.017, rho=0.505, P=0.002, respectively), and FT4 levels (rho=0.302, P=0.006, rho=0.321, P=0.008, respectively) in patients. Duration of disease was significantly correlated with OSI values in patients (rho=0.420, P=0.011), while no correlation with serum TAC levels and TOS levels (P>0.05). Oxidants are increased and antioxidants are decreased in patients with hyperthyroidism; as a result, the oxidative-antioxidative balance is shifted to the oxidative side. Increased oxidative stress may play a role in the pathogenesis of hyperthyroidism. It is believed that supplementation of antioxidant vitamins such as vitamins C and E may be helpful for these patients.
Asunto(s)
Antioxidantes/análisis , Hipertiroidismo/sangre , Oxidantes/sangre , Estrés Oxidativo , Adulto , Algoritmos , Estudios Transversales , Femenino , Bocio Nodular/fisiopatología , Enfermedad de Graves/fisiopatología , Humanos , Hipertiroidismo/etiología , Masculino , Reproducibilidad de los Resultados , Tirotropina/sangre , Tiroxina/sangre , Triyodotironina/sangreRESUMEN
OBJECTIVE: It has been shown that low paraoxonase-1 (PON1) activity is associated with a risk of an early development of atherosclerosis. In the present study, we investigated serum paraoxonase, and arylesterase activities and oxidative stress in patients with adult nephrotic syndrome (NS). In addition, we examined the relationship between these measurements and atherosclerosis. METHODS: Twenty-one patients with NS and 21 healthy controls were enrolled in the study. Serum basal and salt-stimulated paraoxonase activities, arylesterase activity, lipid hydroperoxide (LOOH) and total thiol (SH) levels were measured. RESULTS: Serum basal and salt-stimulated paraoxonase activities, arylesterase activity and total SH levels were significantly lower in patients with NS than in controls (p<0.05, p<0.05, p<0.01 and p<0.05, respectively), whereas LOOH levels were significantly higher (p<0.05). Serum LOOH levels were significantly correlated with total-SH levels in patients with NS (r=-0.467; p<0.01). Moreover, proteinuria levels were significantly correlated with serum LOOH levels (r=0.397; p<0.01), whereas no correlation was found among serum paraoxonase activity, arylesterase activity and total-SH levels in NS patients (p>0.05). CONCLUSIONS: We concluded that oxidative stress is increased, while serum PON1 activity is decreased in patients with adult NS. In addition, these results indicate that lower PON1 activity is associated with an oxidant-antioxidant imbalance that may contribute to atherosclerosis in adult patients with NS.
Asunto(s)
Arildialquilfosfatasa/sangre , Aterosclerosis/sangre , Hidrolasas de Éster Carboxílico/sangre , Síndrome Nefrótico/sangre , Estrés Oxidativo , Adulto , Antioxidantes/química , Biopsia , Femenino , Humanos , Peróxidos Lipídicos/química , Masculino , Persona de Mediana Edad , Oxidantes/química , Estudios Prospectivos , Proteinuria/sangre , Compuestos de Sulfhidrilo/químicaRESUMEN
Renal infarction (RI) is a rarely seen disorder, and the diagnosis is often missed. The two major causes of RI are thromboemboli originhating from a thrombus in the heart or aorta, and in-situ thrombosis of a renal artery. We report a case of RI that developed due to renal artery and vein thrombosis, as confirmed by pathological evaluation of the nephrectomy material, three weeks after renal cyst aspiration.
Asunto(s)
Lesión Renal Aguda/etiología , Quistes/terapia , Infarto/etiología , Enfermedades Renales Quísticas/terapia , Riñón/irrigación sanguínea , Lesión Renal Aguda/cirugía , Anciano , Femenino , Humanos , Infarto/cirugía , Nefrectomía , Arteria Renal/cirugía , Succión/efectos adversos , Trombosis/complicaciones , Trombosis/cirugía , Resultado del Tratamiento , Trombosis de la Vena/complicaciones , Trombosis de la Vena/cirugíaRESUMEN
AIMS AND BACKGROUND: YKL-40 is secreted by several types of tumors. Increased serum YKL-40 levels have been reported in prostate, glioblastoma, breast and colorectal cancers. Determination of YKL-40 levels may serve as a valuable biomarker for the diagnosis and treatment of gastric cancer. The purpose of this study was to determine the serum YKL-40 levels expressed in gastric carcinomas. METHODS: Between 2009 and 2011, we retrospectively reviewed 100 patients with gastric cancer and compared their serum samples to 75 healthy volunteers. YKL-40 levels were determined by an enzyme-linked immunosorbent assay (ELISA). RESULTS: We found significantly higher serum levels of YKL-40 in patients with gastric cancer compared to the healthy population (P < 0.0001). We also found significant differences in serum YKL-40 levels between female and male patients with gastric cancer (P < 0.01). CONCLUSIONS: YKL-40 is over-expressed in gastric cancer, suggesting a more aggressive phenotype. YKL-40 may be a useful serum biomarker for gastric cancer identification, and future studies should focus on the role of YKL-40 in the tumorigenesis of gastric cancer and responsiveness toward treatment.